CN107174535A - A kind of hyaluronic acid compositions and application with the transdermal reparation effect of anti-inflammatory - Google Patents
A kind of hyaluronic acid compositions and application with the transdermal reparation effect of anti-inflammatory Download PDFInfo
- Publication number
- CN107174535A CN107174535A CN201710253509.0A CN201710253509A CN107174535A CN 107174535 A CN107174535 A CN 107174535A CN 201710253509 A CN201710253509 A CN 201710253509A CN 107174535 A CN107174535 A CN 107174535A
- Authority
- CN
- China
- Prior art keywords
- compound
- well mixed
- transdermal
- hyaluronic acid
- deionized water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
A kind of hyaluronic acid compositions and application with the transdermal reparation effect of anti-inflammatory, belong to beauty and skin care healthcare field.Matter acid composition include it is following by weight proportion into subassembly：Hyaluronic acid 0.5 3.0%, compound one 0.5 4.0%, compound 2 0.1 2.0%, deionized water 50 99%, matrix auxiliary material 1.0 50%；Wherein described compound one presses 10 by propane diols and borneol:1 mass ratio compounding is obtained, transdermal enhancer；Described compound two is made up of recombined human hyaluronidase (PH20), sodium chloride, calcium chloride, magnesium sulfate, and each weight ratio of constituents is 1:100:2:1, with safe and efficient percutaneous absorbability.The preparation method of matter acid composition.Comprise the following steps：Take hyaluronic acid and compound two to be dissolved in 35 40 DEG C in 50g deionized water, 1000 3000r/min stirring 3 4h of digestion adjust pH5.0 5.6, add compound one, plus deionized water is saved backup, by increasing matrix auxiliary material to 100 well mixed：For product figuration.
Description
Technical field
The invention belongs to beauty and skin care healthcare field, especially with a kind of with the saturating of the antibacterial transdermal reparation effect of anti-inflammatory
Bright matter acid composition and preparation method thereof is relevant.
Background technology
With the continuous change of human life style, living environment be continually changing and age, psychological pressure, environment are dirty
Dye, seasonal variations, chemical products abuse etc. factor influence, also the skin and skin and mucosa to us bring numerous wounds
Evil, makes skin become coarse generation spot, and continuous ascendant trend is presented in the incidence of disease of disease of skin.Modern medicine study shows,
Human flora lacks of proper care, and pathogenic bacteria grow, and can cause endocrine dysfunction, vivotoxin increases and can not discharged in time, in body
Interior and skin surface is inflamed reaction, so that the toxin expelling for having aggravated skin is born, and time length will endanger the function of skin,
Skin is unable to eupnea and metabolism, will form chloasma, acne, and skin will be dried, lack moisture and oil, dull nothing
Light.Current various skin cosmetic products are simply covered in appearance mostly, the situation of improvement skin that can not be profound, clinical institute
Treatment method is also generally steroids for oral administration, calm class chemicals, and the not good side effect of therapeutic effect is but very big, is skin disease
The treatment of disease brings bigger difficulty, therefore, for the treatment of beautifying skin and disease of skin, particularly chronic skin disease,
Also in the symptomatic treatment stage on clinical treatment, exploitation is safe and effective, and the significant skin problem solution of new generation of effect
It is very important.
The content of the invention
The problem of existing for above-mentioned background technology, the present invention is intended to provide a kind of strengthen the effect of cutaneous immunisation power, makes
Hyaluronic acid compositions and the application with the transdermal reparation effect of anti-inflammatory of skin beauty health.
Therefore, the present invention uses following technical scheme：With the antibacterial transdermal matter acid composition for repairing effect of anti-inflammatory, it is special
Levying is, matter acid composition include it is following by weight proportion into subassembly：Hyaluronic acid 0.5-3.0%, the 0.5- of compound one
4.0%th, the 0.1-2.0% of compound two, deionized water 50-99%, matrix auxiliary material 1.0-50%；Wherein described compound one by
Propane diols and borneol press 10:1 mass ratio compounding is obtained, transdermal enhancer；Described compound two is by recombined human hyalomitome
Sour enzyme (PH20), sodium chloride, calcium chloride, magnesium sulfate composition, each weight ratio of constituents is 1:100:2:1, with safe and efficient transdermal
Absorbability.The preparation method of matter acid composition.Comprise the following steps：Hyaluronic acid and compound two is taken to be dissolved in 50g in 35-40 DEG C
Deionized water in, 1000-3000r/min stirring digestion 3-4h adjust pH5.0-5.6, add compound one, plus deionized water is extremely
100 are well mixed, and save backup, by increasing matrix auxiliary material：For product figuration.
Described matrix auxiliary material has：Glycerine, butanediol, D-sorbite, soluble olive oil, polyethylene glycol 400, ethoxy
It is cellulose, Phenoxyethanol, Sensiva SC50, EDTA-2Na, essence, citric acid, sodium acid carbonate, sodium chloride, sorbierite, thin
Lotus, amino acid foaming agent, sodium benzoate, ethanol, carbomer, carboxymethyl cellulose, potassium hydroxide, preservative, sad glycerine three
Ester, tristerin, B22 emulsifying agents, dimethyl silicone polymer, saualane, rilanit special, aloe extract, lecithin,
One or more compositions form the shaped article of matter acid composition in ceramide, the matrix auxiliary material passed through.
Specific product is as follows：
Make with the antibacterial transdermal method for repairing effect matter acid composition solution of anti-inflammatory, it is characterised in that：A, take it is transparent
Matter acid and compound two are dissolved in 50g deionized water in 37 DEG C, 1000r/min stirring digestion 3h, adjust pH5.5；B, addition are multiple
Fully dissolved with thing one；C plus deionized water are well mixed i.e. available to 100.
Make the method with the antibacterial transdermal facial mask for repairing effect of anti-inflammatory, it is characterised in that：A, take hyaluronic acid and multiple
It is dissolved in thing two in 37 DEG C in 50g deionized water, 1000r/min stirring digestion 3h adjust pH5.5, add compound one abundant
Dissolving；B, the addition after abundant dissolving at 35 DEG C by hydroxyethyl cellulose；C, by glycerine, butanediol, D-sorbite, solubility
Olive oil, polyethylene glycol 400 sequentially add above-mentioned solution, are well mixed, fully dissolve；D, by EDTA-2Na Phenoxyethanols, second
Base hexyl glycerine, essence add above-mentioned solution, are well mixed, fully dissolve.
Make the method with the antibacterial transdermal bath effervescent tablets for repairing effect of anti-inflammatory, it is characterised in that：A, by citric acid
Dry 2 hours, sodium acid carbonate is dried 2 hours under the conditions of 100 DEG C, and 100 mesh sieves were crushed respectively, mix under the conditions of 100 DEG C
Uniformly, sealing is cooled to 40 DEG C；B, hyaluronic acid and compound two is taken to be dissolved in 37 DEG C in 50g deionized water, 1000r/min
Stirring digestion 3h, adjusts pH5.5, adds compound one and fully dissolves, is spray dried to dry powder, adds a and is well mixed；C, by chlorination
Sodium, sorbierite, peppermint, amino acid foaming agent, sodium benzoate, essence add above-mentioned material and are well mixed, grind, and sealing is put in 60
DEG C oven drying 30min；D, the above-mentioned material of Macrogol 4000 addition that will spray ethanol solution, are well mixed, cross 140 mesh
Sieve, is put into tablet press machine and carries out tabletting, produce effervescent tablet.
Make the method for conserving gel with the antibacterial transdermal private portion for repairing effect of anti-inflammatory, it is characterised in that：A, take it is transparent
Matter acid and compound two are dissolved in 50g deionized water in 37 DEG C, 1000r/min stirring digestion 3h, are adjusted pH5.5, are added compounding
Thing one fully dissolves；B, glycerine, sodium chloride, preservative are sequentially added in above-mentioned mixed liquor, with 1000rmp rotating speeds at 25 DEG C
5min is handled, solution is completely dissolved, is well mixed；C, carboxymethyl cellulose, card ripple are sequentially added in above-mentioned mixed liquor
Nurse, handles 100min with 800rmp rotating speeds at 40 DEG C, is completely dissolved thickener, is well mixed；D, a small amount of hydroxide of addition
Potassium, pH is to 4.8 for regulation, and gel is made.
Make the method with the antibacterial transdermal emollient cream for repairing effect of anti-inflammatory, it is characterised in that：A, successively by carboxymethyl
Cellulose, carbomer are added to the water, and handle 100min with 2000rmp rotating speeds at 40 DEG C, are completely dissolved thickener, and mixing is equal
It is even；
B, by Trivent OCG, tristerin, B22 emulsifying agents, dimethyl silicone polymer, saualane, hydrogenation castor
Sesame oil heats consolute at 75 DEG C, it is fully melted, and is well mixed；
C, step a is slowly added to step b, and fully homogeneous, it is well mixed, 45 DEG C are cooled to；
D, hyaluronic acid and compound two is taken to be dissolved in 37 DEG C in 50g deionized water, 1000r/min stirring digestion 3h,
PH5.5 is adjusted, compound one is added and fully dissolves, step c is added and is well mixed,
E, sequentially add glycerine, aloe extract, lecithin, ceramide, homogenization is well mixed it；
F, addition essence, preservative, pH is to 5.5 for regulation, standby.
Following beneficial effect can be reached using the present invention：The present invention is by common hyaluronic acid using safety without anaphylaxis
The shearing of recombined human hyaluronidase, then by a special processing technology processing after, form activation segment, become magical
Almost " guaranteeing to cure mucocutaneous all kinds of diseases and ailments " bioactive materials.Inflammation is source of ten thousand diseases, is also the main of beauty and aging
Reason, the hyaluronic acid after activation is combined with extracellular CD44 and TLR4 acceptors, can promote mucocutaneous secretion defensin 2,
Promote mucocutaneous secretion functional component, and then suppress the inflammatory stimulus effect of inflammation and anti-endotoxin, strengthen cutaneous immunisation
The effect of power, makes skin beauty health.The recombined human hyaluronidase used simultaneously in the hyaluronic acid technique of production activation
Itself it is safe and efficient penetrating agent, it can digest the hyaluronic acid in skin, the viscosity of cytoplasm is reduced, so that temporarily
Skin barrier is opened, makes the direct rapid osmotic of nutriment to dermal layer of the skin and accelerates to spread and absorb, with efficiently oozing
Saturating absorbability, can quickly repair skin.Composition containing hyaluronic acid after activation and multiple efficacies composition is being disappeared using it
Cooperative effect in terms of scorching antibacterial transdermal reparation effect can rationally prevent and solve skin problem, make skin more beautiful strong
Health.The cosmetics of a variety of formulations, including but not limited to water can be made further by adding related matrix or auxiliary material in said composition
Agent, facial mask, lotion, emulsion, frost, cream, gel.
Brief description of the drawings
Fig. 1 is percutaneous absorbability experimental result picture of the invention.
Embodiment
The embodiment to the present invention is described in detail below in conjunction with the accompanying drawings.
The present invention with the antibacterial transdermal matter acid composition for repairing effect of anti-inflammatory include it is following by weight proportion into packet
Close：Hyaluronic acid 0.5-3.0%, the 0.5-4.0% of compound one, the 0.1-2.0% of compound two, deionized water 50-99%, matrix
Auxiliary material 1.0-50%；Wherein described compound one presses 10 by propane diols and borneol:1 mass ratio compounding is obtained, transdermal to promote
Enter agent；Described compound two is made up of recombined human hyaluronidase (PH20), sodium chloride, calcium chloride, magnesium sulfate, each composition
Weight ratio is 1:100:2:1, with safe and efficient percutaneous absorbability.The preparation method of matter acid composition.Comprise the following steps：Take
Hyaluronic acid and compound two are dissolved in 50g deionized water in 35-40 DEG C, 1000-3000r/min stirring digestion 3-4h, are adjusted
PH5.0-5.6, adds compound one, plus deionized water is saved backup, by increasing matrix auxiliary material to 100 well mixed：For
Product figuration Efficacy experiments.
It is as follows that specific product makes embodiment：
(1) embodiment one：Hyaluronic acid compositions solution
First, it is formulated (part by weight)
Hyaluronic acid 1.0%
Compound one 2.0%
Compound 2 1.1%
Plus deionized water is to 100
Two, preparation methods (technical scheme)
A, hyaluronic acid and compound two is taken to be dissolved in 37 DEG C in 50g deionized water, 1000r/min stirring digestion 3h,
Adjust pH5.5；
B, addition compound one fully dissolve；
C plus deionized water are well mixed i.e. available to 100.
(2) embodiment two：Facial mask
First, it is formulated (part by weight)
2nd, preparation method (technical scheme)
A, take hyaluronic acid and compound two to be dissolved in 37 DEG C in 50g deionized water, 1000r/min stirring digestion
3h, adjusts pH5.5, adds compound one and fully dissolves；
B, the addition after abundant dissolving at 35 DEG C by hydroxyethyl cellulose；
C, glycerine, butanediol, D-sorbite, soluble olive oil, polyethylene glycol 400 sequentially added into above-mentioned solution, mixed
Close uniform, fully dissolving；
D, EDTA-2Na Phenoxyethanols, Sensiva SC50, essence added into above-mentioned solution, be well mixed, fully dissolving；
E, tune pH are standby to 5.5.
Embodiment three：Bath effervescent tablets
First, it is formulated (part by weight)
2nd, preparation method (technical scheme)
A, by citric acid under the conditions of 100 DEG C dry 2 hours, sodium acid carbonate under the conditions of 100 DEG C dry 2 hours, respectively
100 mesh sieves were crushed, were well mixed, sealing is cooled to 40 DEG C；
B, hyaluronic acid and compound two is taken to be dissolved in 37 DEG C in 50g deionized water, 1000r/min stirring digestion 3h,
PH5.5 is adjusted, compound one is added and fully dissolves, be spray dried to dry powder, a is added and is well mixed；
C, sodium chloride, sorbierite, peppermint, amino acid foaming agent, sodium benzoate, essence are added into above-mentioned material mix equal
Even, grinding, sealing is put in 60 DEG C of oven drying 30min；
D, the above-mentioned material of Macrogol 4000 addition that will spray ethanol solution, are well mixed, cross 140 mesh sieves, be put into pressure
Piece machine carries out tabletting, produces effervescent tablet.
Example IV：Private portion conserves gel
First, it is formulated (part by weight)
2nd, preparation method (technical scheme)
A, hyaluronic acid and compound two is taken to be dissolved in 37 DEG C in 50g deionized water, 1000r/min stirring digestion 3h,
PH5.5 is adjusted, compound one is added and fully dissolves；
B, glycerine, sodium chloride, preservative are sequentially added in above-mentioned mixed liquor, handled at 25 DEG C with 1000rmp rotating speeds
5min, is completely dissolved solution, is well mixed；
C, sequentially add carboxymethyl cellulose in above-mentioned mixed liquor, carbomer is handled at 40 DEG C with 800rmp rotating speeds
100min, is completely dissolved thickener, is well mixed；
D, a small amount of potassium hydroxide of addition, pH is to 4.8 for regulation, and gel is made.
Embodiment five：Emollient cream
First, it is formulated (part by weight)
2nd, preparation method (technical scheme)
A, carboxymethyl cellulose, carbomer be added to the water successively, 100min handled with 2000rmp rotating speeds at 40 DEG C,
Thickener is completely dissolved, is well mixed；
B, by Trivent OCG, tristerin, B22 emulsifying agents, dimethyl silicone polymer, saualane, hydrogenation castor
Sesame oil heats consolute at 75 DEG C, it is fully melted, and is well mixed；
C, step a is slowly added to step b, and fully homogeneous, it is well mixed, 45 DEG C are cooled to；
D, hyaluronic acid and compound two is taken to be dissolved in 37 DEG C in 50g deionized water, 1000r/min stirring digestion 3h,
PH5.5 is adjusted, compound one is added and fully dissolves, step c is added and is well mixed,
E, sequentially add glycerine, aloe extract, lecithin, ceramide, homogenization is well mixed it；
F, addition essence, preservative, pH is to 5.5 for regulation, standby.
Specific experiment data analysis is carried out to the composition of the present invention below：
First, bacteriostatic experiment
Take Clinical isolation Escherichia coli, staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans a little, connect respectively
Kind in broth bouillon, in cultivating 18h at 37 DEG C.(calf serum that 20% is added in Pseudomonas aeruginosa broth bouillon) takes
Each bacterial strain nutrient broth culture of 18h cultures, being made into bacteria suspension is used to test.Take sterilizing test tubes 11, the 1st addition
Nutrient broth fluid nutrient medium 9ml, 2-10 branch adds 5ml, the 11st addition 10ml, takes the hyaluronic acid of the present embodiment one to combine
Thing solution 1ml adds the 1st test tube, takes 5ml to add the 2nd after being well mixed, the 10th is diluted to successively, the 11st is not loaded
Product are as control.Often pipe cultivates 24h at a temperature of adding escherichia coli suspension 0.1ml, 37 DEG C, takes out observation bacterial growth feelings
Condition.Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans are with above-mentioned Germicidal efficacy growing state.As test tube becomes cloudy, i.e. table
Show bacterial growth, sample is without bacteriostasis；As test tube is limpid, expression bacterial growth is suppressed.Experimental result is as shown in table 1,
Hyaluronic acid compositions solution of the present invention is read Clinical isolation Escherichia coli, staphylococcus aureus, Pseudomonas aeruginosa, white
Pearl bacterium has stronger bacteriostasis.
Each test tube bacterial growth situation in the embodiment one of table 1
| C (Escherichia coli) | C (staphylococcus aureus) | C (Pseudomonas aeruginosa) | C (Candida albicans) | |
| 1 | + | + | + | + |
| 2 | + | + | + | + |
| 3 | + | + | + | + |
| 4 | + | - | - | - |
| 5 | - | - | - | - |
| 6 | - | - | - | - |
| 7 | - | - | - | - |
| 8 | - | - | - | - |
| 9 | - | - | - | - |
| 10 | - | - | - | - |
| 11 | - | - | - | - |
Note："-" represents that test tube becomes cloudy；"+" represents that test tube is limpid.
By above-mentioned limpid broth tubes (1-4) and control group transferred species broth agar plates, 24h, no bacterial growth are observed
Cmin be bacteriocidal concentration, be designated as C, unit is mg/mL, as a result as shown in table 2, illustrate hyaluronic acid of the present invention combination
Thing solution the concentration have to Clinical isolation Escherichia coli, staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans compared with
Strong bactericidal action.
The sterilization conditions of 2 embodiment of table one
| C (Escherichia coli) | C (staphylococcus aureus) | C (Pseudomonas aeruginosa) | C (Candida albicans) | |
| Test tube one | 4.60 | 4.60 | 4.60 | 4.60 |
| Test tube two | 2.30 | 2.30 | 2.30 | 2.30 |
| Test tube three | 1.05 | 1.18 | 1.45 | 1.49 |
| Test tube four | 0.67 | — | — | — |
| Control group | — | — | — | — |
Note："-" indicates no bactericidal properties.
2nd, anti-inflammatory bacteriostatic activity test
The biologically active human of hyaluronic acid compositions solution, the i.e. antibacterial work of anti-inflammatory are now detected using the method for human experimentation
Property, hyaluronic acid compositions solution is studied to prevent and treat inflammatory skin conditions.
Method：The compound two of 0.5%, 2.0%, 3.5% compound one and 0.5%, 1.1%, 2.0% is manufactured respectively
Hyaluronic acid compositions solution other compositions with 0.5%, 1.0%, 2.5% are deionized water, all the components percentage by weight
Summation 100%.All experimenters of this experiment are different degrees of inflammatory skin conditions patient, experiment 1-30 compounds one, compounding
The hyaluronic acid compositions solution of thing two and hyaluronic acid various concentrations smears 1 time before sleeping every night and is carrying out Three factors-levels just
Hand over experiment；Positive control 28-30 is respectively adopted before the hyaluronic acid solution of 0.5 %, 1.0%, 2.5% is slept every night and smeared 1 time,
Situation after observation treatment；31 be that 1 prevention and treatment scytitis disease is smeared before negative control is slept every night using physiological saline
Disease, the situation after observation treatment；Every group of 5 patients, comparison therapy symptom improvement situation after 7 days.
The orthogonal experiment factor meter of table 3：
The symptom therapeutic evaluatioies such as dermal sensation discomfort, inflammation, allergy, peculiar smell, spot：
It is effective：Symptom is significantly improved or disappeared, patient satisfaction；Effectively：Symptom has improvement or mitigated, and patient still has discomfort,
It is required that continual cure；It is invalid：Symptom is unsatisfied with without obvious mitigation, patient.
Statistical method：Statistical procedures are carried out using SPSS12.0 statistics softwares, compared between metering and enumeration data group
Relatively examined using t and x2 is examined, with p<0.05 is statistically significant difference.
The 8th day each group patient symptom of table 4 improves situation and is compared as follows：
Conclusion：Through human body using test, as a result show using 0.5%, 2.0%, 3.5% compound one and 0.5%,
1.1%th, the hyaluronic acid compositions of the hyaluronic acid per distribution ratio of 2.0% compound two and 0.5%, 1.0%, 2.5% are molten
Liquid has prevention and treatment effect to inflammatory skin conditions, but does not limit to this scope.
3rd, percutaneous absorbability is tested
The mouse skin cuticula handled well is fixed on Franz diffusion cells upwards according to Transdermal Absorption experiment, connect
30% ethanol-physiological saline is added in receives pond, is placed in the intelligent penetrating absorption instrument of water bath with thermostatic control, design temperature (37.0 ±
0.5) DEG C, rotating speed 200rmin-1.1h is balanced, sample is added after draining the bubble in reception tank.On diffusion cell supply area
Be uniformly coated with sample 1g, every group parallel 3 times, respectively 0,0.1,0.3,0.5,1.0,2.0,4.0,6.0,8.0,10.0,12.0
When draw reception liquid 1mL, and fill into the reception liquid of equality of temperature same volume.The reception liquid of absorption adds test tube after filtering, then accurately
Add 2mLCTAB test solutions, from add when timing, gently vibrate rock enough long-times, during which trying one's best avoids reaction solution from producing
Raw foam, is stood to close to 10min, then pours into reaction solution in 1cm cuvettes, and wavelength is determined during 10min in 400nm
Absorbance (A400), the transdermal absorption factor of hyaluronic acid is obtained according to the standard curve of hyaluronic acid at that wavelength.
The each sample composition of table 5 composition situation is as follows：
| Hyaluronic acid | Compound one | Compound two | Deionized water | |
| Sample one | 1.0% | 2.0% | 1.1% | To 100 |
| Sample two | 1.0% | 2.0% | — | To 100 |
| Sample three | 1.0% | — | 1.1% | To 100 |
| Control group | 1.0% | — | — | To 100 |
Note："-" represents to be not added with.
Conclusion：Using hyaluronic acid transdermal absorption factor as ordinate, the time (t) is abscissa, draws the transdermal suction of hyaluronic acid
Yield-time graph, as shown in figure 1, result shows that the absorptivity of hyaluronic acid in 12h is the ＞ samples two of one ＞ samples of sample three
＞ control groups, show that hyaluronic acid compositions are remarkably improved the transdermal absorption factor of hyaluronic acid；As a result 0.5h inner skins are shown
Absorption to hyaluronic acid is most fast, and transdermal absorption factor effect of the hyaluronic acid compositions to hyaluronic acid in 0.5h is most obvious.
4th, acute oral toxicity is tested
According to test basis《Disinfection technology standard》(defend method prison hair in the 3.4 of (third edition) first fascicle experimental technique specification
[1999] No. 448).By animal (regular grade NIH mouse 20, male and female half and half, 18~22g of body weight) water supply fasting 12 hours,
Distilled water is solvent, and tested material (hyaluronic acid compositions solution) sets dosage as 5500mg/kg, is filled by 0.2ml/20g body weight
Stomach syringe needle once fills tested material to animal.When being observed immediately after administration and recording the poisoning manifestations, death toll and death of animal
Between, observe secondary daily, two weeks observation periods.Toxicity grading is carried out according to acute toxicity grading criteria.Experimental result：Observation period
Interior, test mice does not occur manifest symptom, no dead generation.
The tested material of table 6 is to NIH chmice acute Oral toxicity result of the tests
| Sex | Dosage (mg/kg) | Number of animals (only) | Death toll (only) | The death rate (%) |
| It is female | 5500 | 10 | 0 | 0 |
| It is male | 5500 | 10 | 0 | 0 |
Conclusion：Hyaluronic acid compositions of the present invention are to the acute through LD50 ＞ 5000mg/kg of NIH mouse, and true border is nontoxic
Level.
5th, vaginal mucosa stimulation test
Press《Disinfection technology standard》(third edition) first fascicle《Experimental technique specification》The 3.5th in (Ministry of Public Health, 2012.4)
Carry out.Healthy White Rabbit 12 is chosen, is divided into experimental group 8, excipient group 2 and blank control group 2.Experimental group：It will apply
The roundlet sliver for having the 2.0cm length of hyaluronic acid compositions test specimen of the present invention inserts experimental animal intravaginal, every kind of sample
Each 2；Excipient group：With the leaching of an equal amount of sliver with sterile saline, animal intravaginal is inserted；Blank group：Do not do and locate
Reason.Sliver is removed after 4 hours, animal is put to death after 24 hours, topical vaginal tissue is taken out, observation whether there is the phenomenons such as hyperemia, oedema.
The sample vaginal mucosa stimulation test of table 7 is as follows：
Note："-" indicates no erythema or edematous condition；" 0 " represents no vaginal irritation reaction.
As a result show, in the observation period, test group, excipient group, blank control group animal topical vaginal tissue are to occur
Erythema or edematous condition, stimulate the reaction integral mean value are 0.According to《Disinfection technology standard》(third edition) first fascicle《Test skill
Art specification》Relevant criterion judges in (Ministry of Public Health, 2012.4), and the present invention is nonirritant to healthy White Rabbit vaginal mucosa.
The general principle and principal character and advantages of the present invention of the present invention has been shown and described above.The technology of the industry
Personnel are it should be appreciated that the present invention is not limited to the above embodiments, and the simply explanation described in above-described embodiment and specification is originally
The principle of invention, without departing from the spirit and scope of the present invention, various changes and modifications of the present invention are possible, these changes
Change and improvement all fall within the protetion scope of the claimed invention.The claimed scope of the invention by appended claims and its
Equivalent thereof.
Claims (7)
1. with the antibacterial transdermal matter acid composition for repairing effect of anti-inflammatory, it is characterised in that：Described matter acid composition include with
Under by weight proportion into subassembly：Hyaluronic acid 0.5-3.0%, the 0.5-4.0% of compound one, the 0.1-2.0% of compound two,
Deionized water 50-99%, matrix auxiliary material 1.0-50%；Wherein described compound one presses 10 by propane diols and borneol:1 quality
Ratio compounding is obtained；Described compound two is made up of recombined human hyaluronidase, sodium chloride, calcium chloride, magnesium sulfate, each composition
Weight ratio is 1:100:2:1.
2. it is according to claim 1 with the antibacterial transdermal matter acid composition for repairing effect of anti-inflammatory, it is characterised in that：It is described
Matrix auxiliary material have：Glycerine, butanediol, D-sorbite, soluble olive oil, polyethylene glycol 400, hydroxyethyl cellulose, benzene oxygen
Ethanol, Sensiva SC50, EDTA-2Na, essence, citric acid, sodium acid carbonate, sodium chloride, sorbierite, peppermint, amino acid foaming
Agent, sodium benzoate, ethanol, carbomer, carboxymethyl cellulose, potassium hydroxide, preservative, Trivent OCG, glycerol stearate
Ester, B22 emulsifying agents, dimethyl silicone polymer, saualane, rilanit special, aloe extract, lecithin, ceramide, pass through
Matrix auxiliary material in one or more compositions form the specific shaped article of matter acid composition.
3. make with the antibacterial transdermal method for repairing effect matter acid composition solution of anti-inflammatory, it is characterised in that：A, take hyalomitome
Acid and compound two are dissolved in 50g deionized water in 37 DEG C, 1000r/min stirring digestion 3h, adjust pH5.5；B, addition compounding
Thing one fully dissolves；C plus deionized water are well mixed i.e. available to 100.
4. make the method with the antibacterial transdermal facial mask for repairing effect of anti-inflammatory, it is characterised in that：A, take hyaluronic acid and compounding
Thing two is dissolved in 50g deionized water in 37 DEG C, 1000r/min stirring digestion 3h, is adjusted pH5.5, is added compound one fully molten
Solution；B, the addition after abundant dissolving at 35 DEG C by hydroxyethyl cellulose；C, by glycerine, butanediol, D-sorbite, soluble olive
Oil, polyethylene glycol 400 sequentially add above-mentioned solution, are well mixed, fully dissolve；D, by EDTA-2Na Phenoxyethanols, ethyl hexyl
Base glycerol, essence add above-mentioned solution, are well mixed, fully dissolve.
5. make the method with the antibacterial transdermal bath effervescent tablets for repairing effect of anti-inflammatory, it is characterised in that：A, by citric acid in
Dried 2 hours under the conditions of 100 DEG C, sodium acid carbonate is dried 2 hours under the conditions of 100 DEG C, 100 mesh sieves were crushed respectively, mixing is equal
Even, sealing is cooled to 40 DEG C；B, hyaluronic acid and compound two is taken to be dissolved in 37 DEG C in 50g deionized water, 1000r/min is stirred
Digestion 3h is mixed, pH5.5 is adjusted, compound one is added and fully dissolves, be spray dried to dry powder, a is added and is well mixed；C, by chlorination
Sodium, sorbierite, peppermint, amino acid foaming agent, sodium benzoate, essence add above-mentioned material and are well mixed, grind, and sealing is put in 60
DEG C oven drying 30min；D, the above-mentioned material of Macrogol 4000 addition that will spray ethanol solution, are well mixed, cross 140 mesh
Sieve, is put into tablet press machine and carries out tabletting, produce effervescent tablet.
6. make the method for conserving gel with the antibacterial transdermal private portion for repairing effect of anti-inflammatory, it is characterised in that：A, take hyalomitome
Acid and compound two are dissolved in 50g deionized water in 37 DEG C, 1000r/min stirring digestion 3h, are adjusted pH5.5, are added compound
One fully dissolving；B, glycerine, sodium chloride, preservative are sequentially added in above-mentioned mixed liquor, at 25 DEG C with 1000rmp rotating speeds at
5min is managed, solution is completely dissolved, is well mixed；C, sequentially add carboxymethyl cellulose in above-mentioned mixed liquor, carbomer,
100min is handled with 800rmp rotating speeds at 40 DEG C, thickener is completely dissolved, is well mixed；D, a small amount of potassium hydroxide of addition, are adjusted
PH is saved to 4.8, gel is made.
7. make the method with the antibacterial transdermal emollient cream for repairing effect of anti-inflammatory, it is characterised in that：
A, carboxymethyl cellulose, carbomer be added to the water successively, 100min is handled with 2000rmp rotating speeds at 40 DEG C, makes increasing
Thick dose is completely dissolved, and is well mixed；
B, by Trivent OCG, tristerin, B22 emulsifying agents, dimethyl silicone polymer, saualane, rilanit special
Consolute is heated at 75 DEG C, it is fully melted, is well mixed；
C, step a is slowly added to step b, and fully homogeneous, it is well mixed, 45 DEG C are cooled to；
D, hyaluronic acid and compound two is taken to be dissolved in 37 DEG C in 50g deionized water, 1000r/min stirring digestion 3h are adjusted
PH5.5, adds compound one and fully dissolves, and adds step c and is well mixed,
E, sequentially add glycerine, aloe extract, lecithin, ceramide, homogenization is well mixed it；
F, addition essence, preservative, pH is to 5.5 for regulation, standby.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710253509.0A CN107174535A (en) | 2017-04-18 | 2017-04-18 | A kind of hyaluronic acid compositions and application with the transdermal reparation effect of anti-inflammatory |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710253509.0A CN107174535A (en) | 2017-04-18 | 2017-04-18 | A kind of hyaluronic acid compositions and application with the transdermal reparation effect of anti-inflammatory |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107174535A true CN107174535A (en) | 2017-09-19 |
Family
ID=59830898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710253509.0A Pending CN107174535A (en) | 2017-04-18 | 2017-04-18 | A kind of hyaluronic acid compositions and application with the transdermal reparation effect of anti-inflammatory |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107174535A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2710074C1 (en) * | 2019-10-02 | 2019-12-24 | Общество с ограниченной ответственностью "МедикалСайнс" | Hydrogel water-soluble composition based on hyaluronic acid and polyvalent metal ions and a method for production thereof |
| JP2021059497A (en) * | 2019-10-03 | 2021-04-15 | 株式会社ナリス化粧品 | Cosmetics for wiping off |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101889966A (en) * | 2010-06-21 | 2010-11-24 | 金奇集团金奇日化有限公司 | Preparation method of tea oil anti-cracking cream composition and product thereof |
| CN102846485A (en) * | 2012-08-31 | 2013-01-02 | 广州市科玮生物技术有限公司 | Chlorophyll sun-screening repair cosmetic |
| CN105267234A (en) * | 2015-10-29 | 2016-01-27 | 山东省药学科学院 | Composition for relieving xerostomia and preparation method thereof |
| CN105603012A (en) * | 2015-12-11 | 2016-05-25 | 天津北洋百川生物技术有限公司 | Preparation method for gamma-polyglutamic acid, and moisturizing face cream and preparation method thereof |
| CN105769605A (en) * | 2016-04-25 | 2016-07-20 | 武文博 | Cosmetic containing human active hyaluronic acid or human active hyaluronate |
| CN106420493A (en) * | 2016-11-21 | 2017-02-22 | 杭州惠博士生物科技有限公司 | Hyaluronic acid toothpaste with effects of diminishing inflammation and inhibiting bacteria and preparation method of hyaluronic acid toothpaste |
-
2017
- 2017-04-18 CN CN201710253509.0A patent/CN107174535A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101889966A (en) * | 2010-06-21 | 2010-11-24 | 金奇集团金奇日化有限公司 | Preparation method of tea oil anti-cracking cream composition and product thereof |
| CN102846485A (en) * | 2012-08-31 | 2013-01-02 | 广州市科玮生物技术有限公司 | Chlorophyll sun-screening repair cosmetic |
| CN105267234A (en) * | 2015-10-29 | 2016-01-27 | 山东省药学科学院 | Composition for relieving xerostomia and preparation method thereof |
| CN105603012A (en) * | 2015-12-11 | 2016-05-25 | 天津北洋百川生物技术有限公司 | Preparation method for gamma-polyglutamic acid, and moisturizing face cream and preparation method thereof |
| CN105769605A (en) * | 2016-04-25 | 2016-07-20 | 武文博 | Cosmetic containing human active hyaluronic acid or human active hyaluronate |
| CN106420493A (en) * | 2016-11-21 | 2017-02-22 | 杭州惠博士生物科技有限公司 | Hyaluronic acid toothpaste with effects of diminishing inflammation and inhibiting bacteria and preparation method of hyaluronic acid toothpaste |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2710074C1 (en) * | 2019-10-02 | 2019-12-24 | Общество с ограниченной ответственностью "МедикалСайнс" | Hydrogel water-soluble composition based on hyaluronic acid and polyvalent metal ions and a method for production thereof |
| JP2021059497A (en) * | 2019-10-03 | 2021-04-15 | 株式会社ナリス化粧品 | Cosmetics for wiping off |
| JP7301707B2 (en) | 2019-10-03 | 2023-07-03 | 株式会社ナリス化粧品 | Cosmetics for wiping |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107184427A (en) | A kind of cooperative compositions and application containing polyglutamic acid and hyaluronic acid | |
| CN110585114B (en) | Bactericidal composition for regulating skin microbial flora and application thereof | |
| CN109568206A (en) | A kind of bacteria inhibiting composition being exclusively used in women and washing lotion and preparation method | |
| CN106309237A (en) | Hyaluronic acid private part care gel and preparation method thereof | |
| CN105287355B (en) | A kind of U.S. flesh anti-acne essence and preparation method thereof | |
| CN107519081A (en) | A kind of composition and preparation method that effect is repaired with anti-acne | |
| CN106619380A (en) | Anti-acne essence | |
| CN107822945A (en) | One kind is matched unartificial yeast composition, preparation method and applied in cosmetics | |
| CN106420491A (en) | Multifunctional skin care product with effects of whitening skin, removing freckles, preserving moisture and removing wrinkle and preparation method of multifunctional skin care product | |
| CN106726896A (en) | A kind of beautifying health composition with anti-inflammatory bacteriostasis efficacy and preparation method thereof | |
| CN104688786A (en) | Externally used pharmaceutical composition, preparation method and application thereof | |
| CN106389139A (en) | Acne-removing, mark-eliminating and skin-protecting multifunctional preparation and preparation method thereof | |
| CN107519236A (en) | A kind of topical agent for treating onychomycosis | |
| CN105963243B (en) | A kind of borneol cinnamomum camphora essential oil sustained release emulsifiable paste and preparation method thereof for treating acne vulgaris | |
| CN107174535A (en) | A kind of hyaluronic acid compositions and application with the transdermal reparation effect of anti-inflammatory | |
| CN109222534A (en) | A kind of pillowcase | |
| CN105963151A (en) | No-preservative composite used for cosmetics corrosion prevention | |
| CN115337233B (en) | Gel mask with mild acne removing effect and preparation method thereof | |
| CN107281001A (en) | A kind of activity conditioning spraying containing hyaluronic acid and preparation method thereof | |
| KR20150122983A (en) | Comsmetic composition comprising mint vinegar | |
| CN109512807A (en) | A kind of Chinese medicine composition and its preparation method and application | |
| CN108324648A (en) | A kind of composition of anti-acne | |
| CN103432049A (en) | Composition with deodorization function | |
| CN105055242B (en) | Gardenoside itching-relieve skin-care dew and preparation method thereof | |
| CN115645460B (en) | Pharmaceutical composition for treating chloasma and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170919 |